Clinical trials: Allergy Pollen
Allergic Rhinoconjunctivitis, Birch Pollen Allergy
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
Allergic rhinoconjunctivitis due to birch pollen is a seasonal problem which manifests as a combination of nasal symptoms (such as congestion, runny nose, sneezing, itching of the nose) and ocular symptoms (such as red, itchy and…
- Trial name
- YOBI (NCT05668390)
- Testing
- STALORAL® Birch 300 IR
- Where
- 62 sites in Austria, Bulgaria and 10 more
- Volunteers
- 553 people
- Sponsor
- Stallergenes Greer
Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy
- Trial name
- NCT04874714
- Testing
- MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000)
- Where
- 13 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Inmunotek S.L.
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH
Rhinitis, Allergic, Nasal Allergy
Mometasone Furoate Nasal Spray in Italian Children
Objective Seasonal allergic rhinitis (SAR) is a common disease in childhood and characterized by type 2 inflammation, bothersome symptoms, and impaired quality of life (QoL).
- Conditions
- Rhinitis, Allergic, Nasal Allergy, Allergy Pollen, Nasal, Cytology
- Trial name
- NCT05301647
- Testing
- Nasal cytology, The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), Total symptom score (TSS)
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Campania Luigi Vanvitelli
Pollen; Allergy, Asthma
Does Medicinal Mushroom Agaricus Blazei Protect Against Allergy and Asthma?
Asthma and allergy is increasing in Norway and Western countries. Treatment is still mostly symptomatic. Extracts of the immunomodulatory and edible mushroom Agaricus blazei, such as Andosan™, have been shown to protect against…
- Trial name
- NCT03198455
- Testing
- Agaricus blazei Murill-based mushroom extract, Andosan™
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Allergy to Grass Pollen, Allergic Rhinitis Due to Weed Pollens
Grass Sensitisation and Allergic Rhinitis in Thai Patients
Allergic rhinitis patients are the patients who have nasal symptoms when triggered by indoor or outdoor allergens. Outdoor allergen can be divided into grass, tree, or weed.
- Trial name
- NCT01686022
- Testing
- Immunoblot
- Where
- Thailand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Grass Pollen Allergy, Specific Immunotherapy
Regulatory T-cells After Subcutaneous Immunotherapy
The primary endpoint was the induction of T-regulatory cells under s specific subcutaneous immunotherapy (SCIT). Patients suffering from grass pollen allergy (relevant clinical symptomes during the pollen season, Skin Prick test…
- Trial name
- RTCAS (NCT01830673)
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Birch Pollen Allergy
A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet
The primary aim of this trial is to evaluate the dose-response relationship for the ALK tree AIT administered once daily in order to define a dose-range that would be suitable for at-home administration.
- Trial name
- NCT01675791
- Testing
- ALK tree AIT 0.5 DU, ALK tree AIT 1 DU, ALK tree AIT 2 DU
- Where
- 2 sites in Finland, Netherlands
- Volunteers
- 637 people
- Sponsor
- ALK-Abelló A/S